רוטה טק (חיסון חי פומי חמש ערכי נגד נגיף הרוטה)

País: Israel

Idioma: hebreu

Font: Ministry of Health

ingredients actius:

ROTAVIRUS G1 REASSORTANT; ROTAVIRUS G2 REASSORTANT; ROTAVIRUS G3 REASSORTANT; ROTAVIRUS G4 REASSORTANT; ROTAVIRUS P1A[8] REASSORTANT

Disponible des:

MERCK SHARP & DOHME (ISRAEL - 1996) COMPANY LTD, ISRAEL

Codi ATC:

J07BH

formulario farmacéutico:

SUSPENSION

Composición:

ROTAVIRUS P1A[8] REASSORTANT 2.3 X10 ^6 IU/DOSE; ROTAVIRUS G2 REASSORTANT 2.8 X10 ^6 IU/DOSE; ROTAVIRUS G4 REASSORTANT 2.0 X10^ 6 IU/DOSE; ROTAVIRUS G3 REASSORTANT 2.2 X10 ^6 IU/DOSE; ROTAVIRUS G1 REASSORTANT 2.2 X10 ^6 IU/DOSE

Vía de administración:

פומי

tipo de receta:

מרשם נדרש

Fabricat per:

MERCK SHARP & DOHME CORP., USA

Grupo terapéutico:

ROTA VIRUS DIARRHEA VACCINES

indicaciones terapéuticas:

RotaTeq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by the serotypes G1, G2, G3, and G4 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. The first dose of RoraTeq should be administered betwen 6 and 12 weeks of age.

Data d'autorització:

2022-05-31